statistical analysis system (sas) software version 8.01 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
statistical analysis system (sas) software version 8.01
Statistical Analysis System (Sas) Software Version 8.01, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+analysis+software+sas%C2%AE+version+8%2E01/sas+version+9+4/pm26091957-78-8-5
Average 90 stars, based on 1 article reviews
Statistical Analysis System (Sas) Software Version 8.01, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+analysis+software+sas%C2%AE+version+8%2E01/sas+version+9+4/pm26091957-78-8-5
Average 90 stars, based on 1 article reviews
statistical analysis system (sas) software version 8.01 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Control:Article Title: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Article Snippet: Aims To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l.. Methods A double-blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin, at 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks, on low-density lipoprotein cholesterol (LDL-C), together with a range of secondary lipid and lipoprotein end points.. Results Rosuvastatin reduced mean LDL-C levels from baseline over 16 weeks by 57.4%, while atorvastatin reduced mean LDL-C levels by 46.0% over the same period. Software:Article Title: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Article Snippet: Aims To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l.. Methods A double-blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin, at 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks, on low-density lipoprotein cholesterol (LDL-C), together with a range of secondary lipid and lipoprotein end points.. Results Rosuvastatin reduced mean LDL-C levels from baseline over 16 weeks by 57.4%, while atorvastatin reduced mean LDL-C levels by 46.0% over the same period. |